Vir Biotechnology Inc. shares tumbled during afternoon trading after the company disclosed that CFO Jason O’Byrne will depart to pursue another opportunity. The stock slid 7.1% to $8.68 in the session and hit a low of $8.62 as sellers outpaced buyers through the afternoon, trading well below the prior close of $9.34.
In a Securities and Exchange Commission filing, Vir confirmed that O’Byrne's resignation "was not related to any disagreement with the company over its operations, policies, or practices." The filing also stated the company has begun a search for his successor. O’Byrne will remain at Vir through August 3 to facilitate a handover before leaving the firm.
Brent Sabatini, who serves as Vir’s Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer. CEO Marianne De Backer sought to steady investor concerns, saying Sabatini has "deep institutional knowledge and financial acumen" and expressing confidence that the financial organization is "in good hands" during the transition.
The timing of the announcement added pressure because Vir is scheduled to report quarterly results on July 30, 2026. That upcoming earnings release means the company will enter a period of Wall Street scrutiny without a permanent CFO in place, a circumstance that can heighten investor caution for clinical-stage companies managing development timelines and capital allocation.
The stock move occurred against a weak tape for growth-focused equities. The NASDAQ Composite was under pressure during the trading session, and the biotech sector - a group often sensitive to leadership changes and cash-burn considerations - did not provide offsetting support for Vir’s shares.
This CFO departure follows the earlier exit of Chief Medical Officer Mark Eisner, who stepped down effective April 24, 2026. The company began a search for Eisner’s successor after that exit. Back-to-back senior leadership departures within a single year can amplify investor concern about organizational stability at a clinical-stage company, particularly when clinical development priorities and capital deployment are ongoing.
On a one-year basis, Vir’s shares have traded between a 52-week low of $4.16 and a 52-week high of $11.66. With the stock around $8.68 following the news, it sits roughly in the middle of that annual range, but the leadership transition and the proximity of the earnings report are likely to keep sentiment cautious until a permanent finance chief is named.
Summary
- Vir’s CFO Jason O’Byrne is leaving to pursue another opportunity; Brent Sabatini is interim CFO.
- Resignation not related to any disagreement, according to an SEC filing; O’Byrne stays through August 3 to assist the transition.
- Company will report earnings on July 30, 2026, without a permanent CFO in place; shares fell amid a weak NASDAQ and biotech sector pressure.